Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 2/20 | 0.43 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 6/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13567377 | 0.91 | XIAP (0.44) | XIAPMLXELANEF2CMA1 | |
| SCHEMBL31615113 | 0.91 | XIAP (0.44) | XIAPMLXELANEACEF2 | |
| SCHEMBL30358379 | 0.91 | ELANE (0.46) | XIAPMLXELANEF2POLB | |
| SCHEMBL30358374 | 0.88 | REN (0.45) | ACEF2REN | |
| SCHEMBL30263777 | 0.85 | REN (0.50) | ACEF2REN | |
| SCHEMBL29411300 | 0.85 | ELANE (0.46) | XIAPMLXELANEACECMA1 | |
| SCHEMBL29966881 | 0.85 | REN (0.46) | ACEF2REN | |
| SCHEMBL30511655 | 0.85 | XIAP (0.49) | XIAPMLXELANEPOLBREN | |
| SCHEMBL23229944 | 0.85 | ACE (0.41) | XIAPMLXELANEACECMA1 | |
| SCHEMBL1404295 | 0.85 | ACE (0.41) | XIAPMLXELANEACECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | XIAP 4200/4885MLX 2416/4885ELANE 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.